Dacarbazine-Vindesine-Cisplatin in Disseminated Malignant Melanoma
| Autor: | Ulrik Ringborg, Johan Hansson, H. Strander, U. Jungnelius |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Cancer Research
medicine.medical_specialty Vindesine Dacarbazine medicine.medical_treatment Phases of clinical research Gastroenterology Nephrotoxicity Ototoxicity Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Neoplasm Metastasis Melanoma Chemotherapy business.industry Remission Induction medicine.disease Surgery Regimen Oncology Drug Evaluation Cisplatin business medicine.drug |
| Zdroj: | American Journal of Clinical Oncology. 13:214-217 |
| ISSN: | 0277-3732 |
| Popis: | Dacarbazine-vindesine-cisplatin treatment was evaluated in a phase II study of patients with disseminated malignant melanoma after the dose of cisplatin had been determined in a phase I study. Dose of dacarbazine was 250 mg/m2 X V every 4 weeks, vindesine 3 mg/m2 once every week, and cisplatin 100 mg/m2 every 4 weeks. Forty patients with advanced disseminated malignant melanoma are available for response. Complete remissions were obtained in three patients (8%) and partial remissions in 12 patients (30%). The total response rate was 38%. Median response duration was 4 months. Toxicity was unacceptable in five cases (nephrotoxicity, one patient; ototoxicity, two patients; hypotonia, one patient; gastrointestinal toxicity, one patient). The conclusion is that the combination dacarbazine-vindesine-cisplatin gives rise to a high response rate in patients with advanced disseminated malignant melanoma. Despite its considerable toxicity, the regimen should be tested on patients with a limited tumor burden. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|